Empower Pharmacy
One of the largest US compounders by volume; dual 503A + 503B. Repeat FDA enforcement history and ongoing Lilly litigation.
High-volume dual 503A/503B pharmacy. Supplies major telehealth partners (Mochi, Lavender Sky). Catalog historically included BPC-157 and CJC-1295/Ipamorelin before Category 2 restrictions; today focused on compoundable peptides (Sermorelin, Tesamorelin, PT-141, Oxytocin, HCG, Gonadorelin, NAD+).
Credentials
- FDA 503B Registered
Flags · curated
- FDA Warning Letter · 2025-04-02Warning letter #700964: sterile drug deficiencies, stopper sterility
- FDA Warning Letter · 2021Prior warning letter
- FDA Warning Letter · 2017Prior warning letter
- Form 483 Observation · 2024Semaglutide fill-weight discrepancies
- Form 483 Observation · 2025-11November 2025 observations
- Ongoing Litigation · 2025-04Eli Lilly suit over compounded tirzepatide with niacinamide/B12 and ODT formulation
Auto-detected · last 12 months
- FDA Warning Letter to Empower Pharmacy and What It Means for 503A Compounding Pharmacies - Buchanan Ingersoll & Rooney PCNews wire · Sep 25, 2026 · Buchanan Ingersoll & Rooney PC
- Statement on FDA’s Warning Letter to Empower Pharmacy for producing drug products in violation of federal law - Partnership for Safe MedicinesNews wire · Sep 23, 2026 · Partnership for Safe Medicines
- FDA takes issue with Empower Pharmacy's GLP-1 production in new warning letter - Houston ChronicleNews wire · Sep 22, 2026 · Houston Chronicle
- Class II: Testosterone Cypionate Injection, 200 mg/mL, CIII, Rx Only, 5 mL Sterile Multip…OpenFDA · May 2, 2025 · Lack of Assurance of Sterility